XENETIC BIOSCIENCES, INC. Deferred Tax Assets, Capital Loss Carryforwards
XENETIC BIOSCIENCES, INC. (XBIO) had Deferred Tax Assets, Capital Loss Carryforwards of $1.26 million as of 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2017-03-31
- 2016-12-31: Deferred Tax Assets, Capital Loss Carryforwards $1.26M.
- 2015-12-31: Deferred Tax Assets, Capital Loss Carryforwards $1.78M.
- 2014-12-31: Deferred Tax Assets, Capital Loss Carryforwards $1.87M.
- 2013-12-31: Deferred Tax Assets, Capital Loss Carryforwards $0.00.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2016-12-31 | $1.26M 10-K · filed 2017-03-31 |
| 2015-12-31 | $1.78M 10-K · filed 2017-03-31 |
| 2014-12-31 | $1.87M 10-K · filed 2016-03-30 |
| 2013-12-31 | $0.00 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |